Drug intelligence / Profile preview

Regansaibisitan Granules

Development stage
Unknown
Lead developer
和田维吾尔药业
Modality
Small Molecules
Administration
Oral
01

Overview

Regansaibisitan (热感赛比斯坦颗粒) is a traditional Uyghur medicine developed and manufactured by Hotan Uyghur Pharmaceutical. It is a multi-herb granule formulation composed of 12 ingredients, including Fructus Corni (破布木果), poppy shell (罂粟壳), and licorice (甘草). The formulation contains natural alkaloids such as morphine, codeine, and papaverine derived from the poppy components, which provide antitussive and analgesic properties. According to traditional Uyghur medical theory, the drug works by clearing abnormal bile fluid, relieving cough, and resolving phlegm. It is primarily indicated for the treatment of hot-type colds accompanied by fever, cough, and respiratory tract infections. The product is approved in China and is listed in the Ministry of Health Drug Standards for Uyghur Medicine.

Brand names
Kunlun Mountain
Other names
热感赛比斯坦颗粒Regansaibisitan KeliRegansaibisitan
02

Targets

JAK2 (Janus kinase 2)STAT3 (Signal Transducer and Activator of Transcription 3)

Beyond the preview

Go deeper on Regansaibisitan Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Regansaibisitan Granules.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call